Form 4: Amneal Pharmaceuticals Director Sells 62,590 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Gautam Patel, a director at Amneal Pharmaceuticals, sold 62,590 shares of Class A Common Stock at an average price of $8.01 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Gautam Patel, a director of Amneal Pharmaceuticals, sold 62,590 shares of Class A Common Stock.
- The sale occurred on January 8, 2025.
- The shares were sold at a weighted average price of $8.01 per share.
- The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on August 15, 2024.
- The sale was part of multiple transactions with prices ranging from $8.00 to $8.04 per share.
- Following the transaction, Patel beneficially owns 1,968,886 shares of Amneal Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a routine filing of an insider stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.
Risks
- Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors. The use of 10b5-1 plans is a legal way for insiders to sell shares while avoiding accusations of trading on non-public information.
Comparison to Industry Standards
- Sales by directors are a normal part of corporate activity, and the use of a 10b5-1 plan is a common practice to avoid insider trading concerns.
- Other pharmaceutical companies will have similar insider trading activity, and the volume of shares sold is not unusual for a director's holdings.
- The price range of $8.00 to $8.04 is within the normal trading range for the stock.
Stakeholder Impact
- The sale of shares by a director could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Date the 10b5-1 trading plan was adopted by the reporting person. |
| 01/08/2025 | Date of the stock sale transaction. |
| 01/09/2025 | Date of the signature on the Form 4 filing. |
Keywords
Amneal Pharmaceuticals, insider trading, Form 4, stock sale, Gautam Patel, 10b5-1 plan, AMRX, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.